Jane Street
VTGN icon

Jane Street’s VistaGen Therapeutics VTGN Stock Holding History

Jane Street’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3K Buy
+23,200
New +$14.1K ﹤0.01% 11274
2025
Q4 		– Sell
-14,500
Closed -$51.5K – 12523
2025
Q3 		$51.5K Buy
+14,500
New +$43.3K ﹤0.01% 10345

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street's VTGN Position: Q1 2026 in Review

Jane Street reduced its VistaGen Therapeutics (VTGN) stake by 48% in Q1 2026, selling an estimated $155K and leaving 272,811 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #10356.

Jane Street first reported a position in VTGN in Q1 2019 and has held it in 12 quarters since. The position peaked at $1.07M in Q3 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Jane Street held 272,811 shares of VistaGen Therapeutics worth $156K as of Q1 2026.
  • Jane Street sold 254,316 VistaGen Therapeutics shares in Q1 2026, an estimated $155K.
  • VistaGen Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10356 holding.
  • Jane Street first reported a position in VistaGen Therapeutics in Q1 2019 and has held it in 12 quarters since.
  • Jane Street's VistaGen Therapeutics position peaked at $1.07M in Q3 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.